Ngan H Y, Cheng G T, Yeung W S, Wong L C, Ma H K
Department of Obstetrics and Gynaecology, University of Hong Kong, Queen Mary Hospital.
Gynecol Oncol. 1994 Jan;52(1):63-8. doi: 10.1006/gyno.1994.1012.
Three hundred two patients with squamous cell carcinoma of the cervix had pretreatment measurement of serum levels of tissue polypeptide antigen (TPA) and squamous cell carcinoma antigen (SCC) to assess their prognostic value. Both markers were of prognostic significance in relation to stage, recurrence, and poor survival. The addition of TPA to SCC did not increase the percentage of patients with elevated pretreatment tumor marker level nor improve the prognostic significance. One hundred thirty-five of these patients also had serial assay of both markers during follow-up. Rise from normal or persistently elevated markers after treatment was associated with recurrence. The median lead time to recurrence was 2 months for SCC and 2.5 months for TPA. The addition of TPA to SCC in serial monitoring increased the sensitivity of detection of recurrence but decreased its specificity. The cost of assay of two markers over one may not justify the slight improvement in sensitivity of detection of recurrence. For squamous cell carcinoma of the cervix, SCC is a better tumor marker than TPA.
302例子宫颈鳞状细胞癌患者在治疗前检测了血清组织多肽抗原（TPA）和鳞状细胞癌抗原（SCC）水平，以评估其预后价值。这两种标志物在分期、复发和不良生存方面均具有预后意义。将TPA加入SCC中，既未增加治疗前肿瘤标志物水平升高的患者比例，也未提高预后意义。其中135例患者在随访期间还对这两种标志物进行了系列检测。治疗后标志物从正常升高或持续升高与复发相关。SCC复发的中位提前期为2个月，TPA为2.5个月。在系列监测中将TPA加入SCC可提高复发检测的敏感性，但降低其特异性。检测两种标志物的成本高于一种，可能无法证明复发检测敏感性的轻微提高是合理的。对于子宫颈鳞状细胞癌，SCC是比TPA更好的肿瘤标志物。
